Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1958 3
1959 1
1961 1
1962 1
1965 1
1966 1
1969 1
1971 1
1975 1
1976 3
1977 1
1978 5
1980 1
1981 2
1982 2
1983 5
1984 4
1985 6
1986 9
1987 5
1988 6
1989 4
1990 7
1991 8
1992 10
1993 15
1994 15
1995 17
1996 14
1997 14
1998 11
1999 11
2000 14
2001 17
2002 14
2003 23
2004 38
2005 33
2006 63
2007 40
2008 49
2009 55
2010 59
2011 67
2012 64
2013 73
2014 70
2015 89
2016 101
2017 118
2018 126
2019 116
2020 139
2021 156
2022 155
2023 150
2024 75

Text availability

Article attribute

Article type

Publication date

Search Results

1,871 results

Results by year

Filters applied: . Clear all
Page 1
Phosphorylation of PDHA by AMPK Drives TCA Cycle to Promote Cancer Metastasis.
Cai Z, Li CF, Han F, Liu C, Zhang A, Hsu CC, Peng D, Zhang X, Jin G, Rezaeian AH, Wang G, Zhang W, Pan BS, Wang CY, Wang YH, Wu SY, Yang SC, Hsu FC, D'Agostino RB Jr, Furdui CM, Kucera GL, Parks JS, Chilton FH, Huang CY, Tsai FJ, Pasche B, Watabe K, Lin HK. Cai Z, et al. Among authors: wu sy. Mol Cell. 2020 Oct 15;80(2):263-278.e7. doi: 10.1016/j.molcel.2020.09.018. Epub 2020 Oct 5. Mol Cell. 2020. PMID: 33022274 Free PMC article.
EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation.
Guo G, Gong K, Beckley N, Zhang Y, Yang X, Chkheidze R, Hatanpaa KJ, Garzon-Muvdi T, Koduru P, Nayab A, Jenks J, Sathe AA, Liu Y, Xing C, Wu SY, Chiang CM, Mukherjee B, Burma S, Wohlfeld B, Patel T, Mickey B, Abdullah K, Youssef M, Pan E, Gerber DE, Tian S, Sarkaria JN, McBrayer SK, Zhao D, Habib AA. Guo G, et al. Among authors: wu sy. Nat Cell Biol. 2022 Aug;24(8):1291-1305. doi: 10.1038/s41556-022-00962-4. Epub 2022 Aug 1. Nat Cell Biol. 2022. PMID: 35915159 Free PMC article.
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Chen L, Jiang YZ, Wu SY, Wu J, Di GH, Liu GY, Yu KD, Fan L, Li JJ, Hou YF, Hu Z, Chen CM, Huang XY, Cao AY, Hu X, Zhao S, Ma XY, Xu Y, Sun XJ, Chai WJ, Guo X, Chen X, Xu Y, Zhu XY, Zou JJ, Yang WT, Wang ZH, Shao ZM. Chen L, et al. Among authors: wu sy. Clin Cancer Res. 2022 Jul 1;28(13):2807-2817. doi: 10.1158/1078-0432.CCR-21-4313. Clin Cancer Res. 2022. PMID: 35247906 Free PMC article.
1,871 results